LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Inicio・Lista de Acciones・Roivant Sciences Ltd

Roivant Sciences Ltd

Abierto

SectorSanidad

30.15 2.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

29.41

Máximo

30.32

Métricas clave
By Trading Economics
Ingresos	669M 356M
Ventas	521K 2.5M
Margen de beneficios	14,116.825
Empleados	721
EBITDA	-65M -354M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+27.89% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.3B 21B
Apertura anterior	27.6
Cierre anterior	30.15

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

50 / 344 Clasificación en Healthcare

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 may 2026, 22:47 UTC

Ganancias

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 may 2026, 20:45 UTC

Ganancias

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 may 2026, 23:39 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 may 2026, 23:31 UTC

Charlas de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 may 2026, 23:17 UTC

Charlas de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 may 2026, 23:02 UTC

Charlas de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 may 2026, 22:37 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 may 2026, 21:12 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 may 2026, 21:00 UTC

Ganancias

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 may 2026, 20:57 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:55 UTC

Ganancias

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

28 may 2026, 20:48 UTC

Acciones populares

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 may 2026, 20:34 UTC

Ganancias

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 may 2026, 20:31 UTC

Ganancias

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 may 2026, 20:28 UTC

Ganancias

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 may 2026, 20:26 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Membership Fees $1.37B

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Net Sales $69.15B

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

27.89% repunte

Estimación a 12 Meses

Media 37.83 USD 27.89%

Máximo 42 USD

Mínimo 31.5 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Roivant Sciences Ltd Dist en los últimos 3 meses.

Sentimiento

By Acuity

50 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.